Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the leading causes of workplace absence, carpal tunnel syndrome, can be treated successfully with decompression surgery without serious complications according to research from NDORMS.

Carpal tunnel syndrome

Pain in the wrist, tingling and numbness, and in severe cases, thumb weakness are all symptoms of carpal tunnel syndrome, the most common nerve problem. Caused by compression of the median nerve within the carpal tunnel at the level of the wrist, the condition affects between 5 -10% of the population.

Most patients require surgery to decompress the carpal tunnel and retain hand function, but until now data on safety and effectiveness of the operation remained scarce.

Jennifer Lane, Versus Arthritis Clinical Research Fellow in Trauma and Orthopaedic Surgery explained: "Earlier studies may have overestimated the levels of major or minor complications seen in patients following decompression treatment leaving patients with mixed messages. Our aim was to identify the true scale of either reoperation or serious complications within patient groups, and also to improve the advice available for those patients at greater risk."

The team did a nationwide cohort analysis of all carpal tunnel decompression surgeries in patients aged 18 years or older, performed in the National Health Service in England between April 1, 1998, and March 31, 2017. 855 832 records were examined, making the study what is thought to be the largest national study on carpal tunnel decompression to date.

They were looking for the incidence of reoperation within 30 days and 90 days after surgery, or of serious postoperative complications such as nerve, vascular or tendon injury. Minor complications including pain, infection or scar disorders that did not require further admission to hospital or surgery were also measured.

Overall rates of reoperation or serious complications were very low. The 90-day local serious complication rate was 0·082%, and only 3.4% of cases went on to need a reoperation.

Looking further into demographic groups, excess risk of reoperation was associated with males in the older age bracket (>80 years) and those with greater levels of comorbidities, and socioeconomic deprivation. By contrast, local serious complications in the first 90 days after surgery were more likely in men and younger patients aged 18–29 years but without comorbidities.

"From the available evidence we have found that Carpal tunnel decompression surgery, as practiced in the National Health Service in England, appears to be safe," said Jenny. "This should help clinicians in their understanding of the role of decompression surgery within the treatment of carpal tunnel syndrome, and guide personalised shared decision making."

The study was funded by Versus Arthritis; Medical Research Council; Royal College of Surgeons of England and National Joint Registry research fellowship; University of Oxford; National Institute for Health Research; and National Institute for Health Research Biomedical Research Centre, Oxford.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.